Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.60 -0.19 (-1.07%)
Streaming Delayed Price Updated: 10:20 AM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Analyst Expectations for Bausch & Lomb's Future ↗
 
Via Benzinga
News headline image
Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology
From Bausch + Lomb Corporation
Via Business Wire
News headline image
The Latest Analyst Ratings for Bausch & Lomb ↗
 
Via Benzinga
7 Analysts Have This to Say About Bausch & Lomb ↗
 
Via Benzinga
What 7 Analyst Ratings Have To Say About Bausch & Lomb ↗
 
Via Benzinga
News headline image
Expert Ratings for Bausch & Lomb ↗
Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 ↗
 
Via Benzinga
News headline image
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Trade Desk, Roblox, Herbalife And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Bausch & Lomb ↗
Analysts have provided the following ratings for Bausch & Lomb (NYSE:BLCO) within the last quarter: 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Bausch & Lomb ↗
Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023
From Bausch + Lomb Corporation
Via Business Wire
News headline image
New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Expert Ratings for Bausch & Lomb ↗
Within the last quarter, Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings: 
Via Benzinga
News headline image
Expert Ratings for Bausch & Lomb ↗
  Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Acquires AcuFocus, Inc.
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022 ↗
 
Via Benzinga
News headline image
Battered FTX's CEO Sam Bankman-Fried Arrested, Elon Musk's SpaceX Mammoth Valuation Of $140B, China Weighs Over $143B In Semiconductor Push: Top Stories Tuesday, Dec. 13 ↗
Benzinga Sam Bankman-Fried Arrested In The Bahamas 
Via Benzinga
News headline image
Bausch Health Investors Request Blocking Eye-Care Business Spinoff, Alleging Protection From Lawsuits ↗
More than 50 funds that own Bausch Health Companies Inc (NYSE: BHC) investors are reportedly seeking to block the eye-care business spin-off, Bausch + Lomb Corp (NYSE: BLCO). 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2022 ↗
Upgrades 
Via Benzinga
News headline image
From Corporate Raider To Activist Investor: Here Are Three High-Yielding Stocks Carl Icahn Favors ↗
Formerly known as a "corporate raider," Carl Icahn is the founder and controlling shareholder of Icahn Enterprises, which is a large holding company with well diversified positions. 
Via Benzinga
News headline image
BHC Stock Continues to Fall as Bausch Health Responds to Court Decision ↗
Although Bausch Health promises to fight back against an unfavorable patent protection ruling, BHC stock is still hurting. 
Via InvestorPlace
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.